Sequent Scientific Ltd reported financial results for Q4 FY25, with revenues of ₹4,017 million (up 11.2%) and EBITDA of ₹569 million (up 38.7%), along with an annual revenue of ₹15,514 million (up 13.3%) and EBITDA of ₹1,993 million (up 86.6%). The announcement includes ongoing plans for a merger with Viyash Life Sciences.